Research programme: pegylated GM-CSF - Cangene

Drug Profile

Research programme: pegylated GM-CSF - Cangene

Alternative Names: Research programme: PEG granulocyte macrophage colony-stimulating factor - Cangene; Research programme: PEG-GM-CSF - Cangene

Latest Information Update: 28 Feb 2014

Price : $50

At a glance

  • Originator Cangene Corporation
  • Class
  • Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 21 Feb 2014 Emergent BioSolutions acquires Cangene Corporation
  • 22 Feb 2006 Preclinical trials in Neutropenia in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top